PLX Protalix BioTherapeutics Inc. (DE)

0.59
-0.03  -5%
Previous Close 0.62
Open 0.60
Price To book -3.69
Market Cap 78679473
Shares 133,355,039
Volume 642,556
Short Ratio 10.11
Av. Daily Volume 599,577

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to commence 3Q 2017.
Pegunigalsidase alfa (PRX-102)
Fabry Disease
Approved May 1, 2012.
Taliglucerase alfa
Gaucher disease
Phase 3 dosing commenced October 2016. Enrollment to be completed 2H 2017 with data in 2018.
PRX-102
Fabry disease
Phase 2 interim data released January 3, 2017. Full data released April 12, 2017. Company noted data were positive but results showed efficacy down on January data.
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2 trial initiation announced November 30, 2016. Data due around the end of 2017.
OPRX-106
Ulcerative Colitis